Condition
Gitelman Syndrome
Total Trials
6
Recruiting
2
Active
2
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 4 (1)
Trial Status
Completed4
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06922370RecruitingPrimary
The Osteoarticular Manifestations in Patients With Gitelman Syndrome
NCT04995627Not ApplicableCompletedPrimary
Salt Supplementation in Gitelman Syndrome
NCT06065852Recruiting
National Registry of Rare Kidney Diseases
NCT00822107Not ApplicableCompletedPrimary
A Translational Approach to Gitelman Syndrome
NCT02297048Phase 4CompletedPrimary
Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)
NCT01146197Phase 1CompletedPrimary
Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics
Showing all 6 trials